166 related articles for article (PubMed ID: 27729458)
1. Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma.
Hart LS; Rader J; Raman P; Batra V; Russell MR; Tsang M; Gagliardi M; Chen L; Martinez D; Li Y; Wood A; Kim S; Parasuraman S; Delach S; Cole KA; Krupa S; Boehm M; Peters M; Caponigro G; Maris JM
Clin Cancer Res; 2017 Apr; 23(7):1785-1796. PubMed ID: 27729458
[No Abstract] [Full Text] [Related]
2. Dual
Wood AC; Krytska K; Ryles HT; Infarinato NR; Sano R; Hansel TD; Hart LS; King FJ; Smith TR; Ainscow E; Grandinetti KB; Tuntland T; Kim S; Caponigro G; He YQ; Krupa S; Li N; Harris JL; Mossé YP
Clin Cancer Res; 2017 Jun; 23(11):2856-2868. PubMed ID: 27986745
[No Abstract] [Full Text] [Related]
3. Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression.
Woodfield SE; Zhang L; Scorsone KA; Liu Y; Zage PE
BMC Cancer; 2016 Mar; 16():172. PubMed ID: 26925841
[TBL] [Abstract][Full Text] [Related]
4.
Valencia-Sama I; Ladumor Y; Kee L; Adderley T; Christopher G; Robinson CM; Kano Y; Ohh M; Irwin MS
Cancer Res; 2020 Aug; 80(16):3413-3423. PubMed ID: 32586982
[TBL] [Abstract][Full Text] [Related]
5. YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling.
Coggins GE; Farrel A; Rathi KS; Hayes CM; Scolaro L; Rokita JL; Maris JM
Cancer Res; 2019 Dec; 79(24):6204-6214. PubMed ID: 31672841
[TBL] [Abstract][Full Text] [Related]
6. Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition.
Mayes PA; Degenhardt YY; Wood A; Toporovskya Y; Diskin SJ; Haglund E; Moy C; Wooster R; Maris JM
Int J Cancer; 2013 Feb; 132(3):E149-57. PubMed ID: 22948716
[TBL] [Abstract][Full Text] [Related]
7. Limited antitumor activity of combined BET and MEK inhibition in neuroblastoma.
Healy JR; Hart LS; Shazad AL; Gagliardi ME; Tsang M; Elias J; Ruden J; Farrel A; Rokita JL; Li Y; Wyce A; Barbash O; Batra V; Samanta M; Maris JM; Schnepp RW
Pediatr Blood Cancer; 2020 Jun; 67(6):e28267. PubMed ID: 32307821
[TBL] [Abstract][Full Text] [Related]
8. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations.
Eleveld TF; Oldridge DA; Bernard V; Koster J; Colmet Daage L; Diskin SJ; Schild L; Bentahar NB; Bellini A; Chicard M; Lapouble E; Combaret V; Legoix-Né P; Michon J; Pugh TJ; Hart LS; Rader J; Attiyeh EF; Wei JS; Zhang S; Naranjo A; Gastier-Foster JM; Hogarty MD; Asgharzadeh S; Smith MA; Guidry Auvil JM; Watkins TB; Zwijnenburg DA; Ebus ME; van Sluis P; Hakkert A; van Wezel E; van der Schoot CE; Westerhout EM; Schulte JH; Tytgat GA; Dolman ME; Janoueix-Lerosey I; Gerhard DS; Caron HN; Delattre O; Khan J; Versteeg R; Schleiermacher G; Molenaar JJ; Maris JM
Nat Genet; 2015 Aug; 47(8):864-71. PubMed ID: 26121087
[TBL] [Abstract][Full Text] [Related]
9. In vivo effects of short- and long-term MAPK pathway inhibition against neuroblastoma.
Takeuchi Y; Tanaka T; Higashi M; Fumino S; Iehara T; Hosoi H; Sakai T; Tajiri T
J Pediatr Surg; 2018 Dec; 53(12):2454-2459. PubMed ID: 30266481
[TBL] [Abstract][Full Text] [Related]
10. MEK inhibitors as a novel therapy for neuroblastoma: Their in vitro effects and predicting their efficacy.
Tanaka T; Higashi M; Kimura K; Wakao J; Fumino S; Iehara T; Hosoi H; Sakai T; Tajiri T
J Pediatr Surg; 2016 Dec; 51(12):2074-2079. PubMed ID: 27686482
[TBL] [Abstract][Full Text] [Related]
11. The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma.
Lowery CD; VanWye AB; Dowless M; Blosser W; Falcon BL; Stewart J; Stephens J; Beckmann RP; Bence Lin A; Stancato LF
Clin Cancer Res; 2017 Aug; 23(15):4354-4363. PubMed ID: 28270495
[No Abstract] [Full Text] [Related]
12. Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition.
Zhang L; Scorsone K; Woodfield SE; Zage PE
Cancer Chemother Pharmacol; 2015 Nov; 76(5):977-87. PubMed ID: 26407819
[TBL] [Abstract][Full Text] [Related]
13. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.
Gilmartin AG; Bleam MR; Groy A; Moss KG; Minthorn EA; Kulkarni SG; Rominger CM; Erskine S; Fisher KE; Yang J; Zappacosta F; Annan R; Sutton D; Laquerre SG
Clin Cancer Res; 2011 Mar; 17(5):989-1000. PubMed ID: 21245089
[TBL] [Abstract][Full Text] [Related]
14. A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.
Geoerger B; Bourdeaut F; DuBois SG; Fischer M; Geller JI; Gottardo NG; Marabelle A; Pearson ADJ; Modak S; Cash T; Robinson GW; Motta M; Matano A; Bhansali SG; Dobson JR; Parasuraman S; Chi SN
Clin Cancer Res; 2017 May; 23(10):2433-2441. PubMed ID: 28432176
[No Abstract] [Full Text] [Related]
15. Dual inhibition using cabozantinib overcomes HGF/MET signaling mediated resistance to pan-VEGFR inhibition in orthotopic and metastatic neuroblastoma tumors.
Daudigeos-Dubus E; Le Dret L; Bawa O; Opolon P; Vievard A; Villa I; Bosq J; Vassal G; Geoerger B
Int J Oncol; 2017 Jan; 50(1):203-211. PubMed ID: 27922668
[TBL] [Abstract][Full Text] [Related]
16. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.
Troiani T; Napolitano S; Vitagliano D; Morgillo F; Capasso A; Sforza V; Nappi A; Ciardiello D; Ciardiello F; Martinelli E
Clin Cancer Res; 2014 Jul; 20(14):3775-86. PubMed ID: 24812410
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.
Lee MS; Helms TL; Feng N; Gay J; Chang QE; Tian F; Wu JY; Toniatti C; Heffernan TP; Powis G; Kwong LN; Kopetz S
Oncotarget; 2016 Jun; 7(26):39595-39608. PubMed ID: 27167191
[TBL] [Abstract][Full Text] [Related]
18. Metformin increases antitumor activity of MEK inhibitor binimetinib in 2D and 3D models of human metastatic melanoma cells.
Ryabaya O; Prokofieva A; Akasov R; Khochenkov D; Emelyanova M; Burov S; Markvicheva E; Inshakov A; Stepanova E
Biomed Pharmacother; 2019 Jan; 109():2548-2560. PubMed ID: 30551515
[TBL] [Abstract][Full Text] [Related]
19. Deletion of 11q in Neuroblastomas Drives Sensitivity to PARP Inhibition.
Sanmartín E; Muñoz L; Piqueras M; Sirerol JA; Berlanga P; Cañete A; Castel V; Font de Mora J
Clin Cancer Res; 2017 Nov; 23(22):6875-6887. PubMed ID: 28830922
[No Abstract] [Full Text] [Related]
20. CXCR4 Promotes Neuroblastoma Growth and Therapeutic Resistance through miR-15a/16-1-Mediated ERK and BCL2/Cyclin D1 Pathways.
Klein S; Abraham M; Bulvik B; Dery E; Weiss ID; Barashi N; Abramovitch R; Wald H; Harel Y; Olam D; Weiss L; Beider K; Eizenberg O; Wald O; Galun E; Pereg Y; Peled A
Cancer Res; 2018 Mar; 78(6):1471-1483. PubMed ID: 29259008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]